Gubra AS GUBRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- DKK 277.00
- Day Range
- DKK 278.00–285.00
- 52-Week Range
- DKK 83.45–346.00
- Bid/Ask
- DKK 282.00 / DKK 284.00
- Market Cap
- DKK 4.59 Bil
- Volume/Avg
- 9,608 / 62,062
Key Statistics
- Price/Earnings (Normalized)
- 377.10
- Price/Sales
- 20.50
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. It has three segments: Pre-clinical contract research (CRO), which derives maximum revenue; Discovery & Partnerships (D&P) Segment; and Gubra Green Segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 219
- Website
- https://www.gubra.dk
Comparables
Valuation
Metric
|
GUBRA
|
BAVA
|
PNT
|
---|---|---|---|
Price/Earnings (Normalized) | 377.10 | 5.72 | 11.36 |
Price/Book Value | 9.41 | 1.14 | 3.12 |
Price/Sales | 20.50 | 1.64 | 5.50 |
Price/Cash Flow | — | 4.34 | 13.90 |
Price/Earnings
GUBRA
BAVA
PNT
Financial Strength
Metric
|
GUBRA
|
BAVA
|
PNT
|
---|---|---|---|
Quick Ratio | 6.40 | 1.33 | 9.01 |
Current Ratio | 6.45 | 1.94 | 9.14 |
Interest Coverage | −8.73 | 14.67 | — |
Quick Ratio
GUBRA
BAVA
PNT
Profitability
Metric
|
GUBRA
|
BAVA
|
PNT
|
---|---|---|---|
Return on Assets (Normalized) | −7.38% | 15.06% | 20.67% |
Return on Equity (Normalized) | −10.20% | 22.77% | 23.56% |
Return on Invested Capital (Normalized) | −8.49% | 21.52% | 23.38% |
Return on Assets
GUBRA
BAVA
PNT
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bbjjfrchc | Dgfm | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xndkmdg | Bfkcnwc | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sjczftp | Hxnhy | $97.8 Bil | |
MRNA
| Moderna Inc | Gtnhcfth | Bsmvx | $41.3 Bil | |
ARGX
| argenx SE ADR | Fkrscck | Ncsyc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Zgjwwvlw | Tmrzc | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Csmjzplnf | Mcnjws | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jtpghvtz | Qnfbqg | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fgrvfbhbh | Pjsvkt | $12.5 Bil | |
INCY
| Incyte Corp | Typptsfmk | Lcdyszn | $11.6 Bil |